Holen Sie sich die Stockscreener-App
5.13
1.38%
0.07
Handel nachbörslich:
5.19
0.06
+1.17%
Schlusskurs vom Vortag:
$5.06
Offen:
$5
24-Stunden-Volumen:
37.94M
Relative Volume:
1.66
Marktkapitalisierung:
$2.22B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.3097
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-1.72%
1M Leistung:
+22.73%
6M Leistung:
-24.11%
1J Leistung:
-31.23%
1-Tages-Spanne:
$4.91
$5.44
1-Wochen-Bereich:
$4.91
$5.48
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.13 | 2.22B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia
Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India
Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Recursion Pharma to reduce workforce by 20% - MSN
Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada
Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks
Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com
Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges - TipRanks
Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN
Recursion to lay off 20% of workforce amid biotech funding woes - MSN
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN
After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma
Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga
Recursion Downsizes by 20% To Boost Cash Position - BioSpace
Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - marketscreener.com
Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha
Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - MarketScreener
Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets
Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus
Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks
Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks
Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com
15 Stocks That Stole The Show Last Week - Insider Monkey
Recursion rises on launch of Boltz-2 in partnership with MIT - MSN
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey
10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey
Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga
Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals shares surge on AI model release - Investing.com
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus
Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):